Open access
Open access
Powered by Google Translator Translator

RCT | Triglyceride lowering with Pemafibrate fails to reduce CVD risk in patients with Type 2 DM and hypertriglyceridemia.

7 Nov, 2022 | 12:54h | UTC

Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk – New England Journal of Medicine (link to abstract – $ for full-text)

News Releases:

New medicine reduces triglyceride by 25%, no change in CVD risk in people with Type 2 diabetes – American Heart Association

Triglyceride-lowering trial neutral for cardiovascular event reduction – Brigham and Women’s Hospital


Pemafibrate Fails to Lower CVD Risk in Patients With High Triglycerides: PROMINENT – TCTMD

PROMINENT: Pemafibrate Effective in Lowering Tryglycerides, But Not Reducing Risk of CV Events – American College of Cardiology


Commentary on Twitter


Stay Updated in Your Specialty

No spam, just news.